Adam Goulburn is a Co-Founder and Managing Partner at Dimension Capital. See contact routes.
Adam Goulburn is a Co-Founder and Managing Partner at Dimension Capital, a New York-based venture firm he launched in March 2022 alongside former Lux Capital colleagues Zavain Dar and Nan Li from Obvious Ventures. His investment thesis targets the intersection of biotechnology and technology, focusing on early-stage companies (seed to Series A) that develop platform technologies merging biotech with computing or tools to accelerate drug discovery. Dimension operates as an early-stage firm aiming to be the first institutional investor, with a typical check size averaging $35.3 million and a maximum of $55 million, often leading rounds. Notable portfolio companies include Enveda Biosciences, Kaleidoscope Bio, Eikon Therapeutics, and Kallyope, the latter two being startups Goulburn previously backed at Lux Capital. Goulburn holds a PhD in Stem Cell Research and previously served as Founding CEO at VNV Bio (now Aera Therapeutics), giving him a distinctive operator-scientist perspective on tech-powered biotech. He publicly emphasizes breaking down silos between life sciences and technology to create synergies in areas like AI-driven drug discovery.
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in New York.
Investors like Adam Goulburn · Full investor directory · Investor access · Company funding database